Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

A new study found the drug kept head and neck cancers at bay for five years compared to 30 months with standard care ...

A grandad diagnosed with stage 4 lung cancer–one of the deadliest—has become disease-free after being treated with an ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive ...

A grandad with advanced lung cancer, which often leaves patients dead within four months has become free of the disease after ...

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: ...